Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Kenro HirataYasuo HamamotoMasahiko AndoChiyo K ImamuraKenichi YoshimuraKentaro YamazakiShuichi HironakaKei MuroPublished in: BMC cancer (2020)
This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs031180022, October 1, 2018).